Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome (ASAPIII)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University Medical Centre Groningen
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Dr. H. Bootsma, University Medical Centre Groningen
ClinicalTrials.gov Identifier:
NCT02067910
First received: February 14, 2014
Last updated: August 21, 2014
Last verified: August 2014
  Purpose

Primary Sjögren's syndrome (pSS) is a common chronic auto-immune disease, characterised by inflammation of the exocrine glands, resulting in progressive dryness of the eyes and the mouth. Furthermore, many patients experience extraglandular symptoms such as restricting fatigue. Currently, biological agents have been introduced in various systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. No biological agent has yet been approved for the treatment of pSS. In an open-label study, we have shown that abatacept treatment of pSS patients has promising results (Meiners et al., 2014). Therefore, the aim of this study is to evaluate efficacy and safety of subcutaneous abatacept treatment in pSS in a larger and randomized clinical trial.


Condition Intervention Phase
Sjögren's Syndrome
Drug: Abatacept SC
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome (ASAP III Study = Abatacept Sjögren Active Patients Phase III Study)

Resource links provided by NLM:


Further study details as provided by University Medical Centre Groningen:

Primary Outcome Measures:
  • ESSDAI [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety parameters [ Time Frame: Week 4, 8, 12, 24, 28, 32, 36, 48 ] [ Designated as safety issue: Yes ]
    Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) v.14.0.

  • ESSDAI (at time-points other than 24 weeks) [ Time Frame: Week 0, 4, 8, 12, 28, 32, 36, 48 ] [ Designated as safety issue: No ]
  • DAS28(CRP) and DAS28(ESR) [ Time Frame: Week 0, 4, 8, 12, 24, 28, 32, 36, 48 ] [ Designated as safety issue: No ]
  • Corticosteroid dose (decrease, stable, increase) [ Time Frame: Week 0, 4, 8, 12, 24, 28, 32, 36, 48 ] [ Designated as safety issue: No ]
  • Salivary gland function [ Time Frame: Week 0, 12, 24, 36 and 48 ] [ Designated as safety issue: No ]
    Unstimulated and stimulated whole saliva, sialometric and sialochemical analysis of gland-specific saliva

  • Tear gland function [ Time Frame: Week 0, 12, 24, 36 and 48 ] [ Designated as safety issue: No ]
    Schirmer test, tear-break-up time, ocular staining score, tears collection, determination of auto-antibodies and cytokines, conjunctival impression cytology

  • ESSPRI [ Time Frame: 0, 4, 8, 12, 24, 28, 32, 36, and 48. ] [ Designated as safety issue: No ]
  • Patient and Physician Global assessment of disease activity (patGDA, phyGDA) [ Time Frame: 0, 4, 8, 12, 24, 28, 32, 36, and 48 ] [ Designated as safety issue: No ]
  • Multidimensional Fatigue Index (MFI) [ Time Frame: week 0, 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Health related quality of life (Short Form-36; SF-36) [ Time Frame: week 0, 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Patient Acceptable Symptom State (PASS) [ Time Frame: week 0, 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Female Sexual Function Index (FSFI) [ Time Frame: week 0, 24 and 48 ] [ Designated as safety issue: No ]
  • NRS score vaginal dryness [ Time Frame: Week 0, 24 and 48 ] [ Designated as safety issue: No ]
  • Histological change in parotid gland [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    Follow-up parotid gland biopsy in patients of who a recent (<6 months prior to inclusion) parotid gland biopsy is available.

  • Laboratory immune markers [ Time Frame: Week 0, 4, 8, 12, 24, 28, 32, 36 and 48 ] [ Designated as safety issue: No ]
    Serum levels of ANA and IgM-Rf, Serum levels of anti-SSA, anti-SSB, Immunoglobulins (IgG, IgA, IgM), T and B cell subsets, Cytokines, Free light chain, MxA, β2 microglobulin, Complement (C3 and C4), CRP, ESR

  • EQ-5D [ Time Frame: Week 0, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
  • Work Participation and Activity Impairment questionnaire (WPAI) [ Time Frame: Week 0, 12, 24, 36 and 48 ] [ Designated as safety issue: No ]

Estimated Enrollment: 88
Study Start Date: August 2014
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Abatacept SC
Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
Drug: Abatacept SC
Weekly subcutaneous administration of 125 mg Abatacept
Other Names:
  • Subcutaneous Abatacept
  • Orencia
Placebo Comparator: Placebo
First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
Drug: Abatacept SC
Weekly subcutaneous administration of 125 mg Abatacept
Other Names:
  • Subcutaneous Abatacept
  • Orencia

Detailed Description:

Background: Primary Sjögren's syndrome (pSS) is a chronic inflammatory and lymphoproliferative disease with autoimmune features. pSS is characterised by a progressive lymphocytic infiltration of the exocrine glands, notably the lacrimal and salivary glands. The main clinical features are a progressive dryness of the eyes, mouth, vagina and skin. Furthermore, various extraglandular manifestations may develop of which restricting fatigue is the most common. Patients may be restricted in their activities and their participation in society, resulting in a reduced health-related quality of life and an impaired socioeconomic status. The latter results in lower employment rates and more disability as compared to the general population. The estimated prevalence of pSS in the general population is between 0.5-2%, which makes pSS, after rheumatoid arthritis (RA), the most common systemic autoimmune disease. Most of the traditional anti-rheumatic drugs used in RA and systemic lupus erythematosus have been tried in pSS with limited results. Currently, biological agents have been introduced in various systemic autoimmune diseases. These biological agents enhance or replace conventional immunosuppressive therapy. In contrast to RA and systemic lupus erythematosus (SLE), no biological agent has yet been approved for the treatment of pSS. Abatacept is a fully human soluble co-stimulation modulator that selectively targets the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation, and T cell dependent activation of B-cells. We have recently shown in a phase II open label study that Abatacept treatment of pSS patients has promising efficacy results, as reflected by a significant decrease in disease activity indices such as the EULAR Sjögrens Syndrome Disease Activity Index and Patient Reported Index (ESSDAI and ESSPRI) (Meiners et al., 2014). Importantly, we also have shown that Abatacept is safe and side effects are very limited in pSS patients. For these reasons a larger and randomized clinical trial with Abatacept is warranted.

Objective: Primary: to evaluate efficacy of weekly subcutaneous (SC) administration of Abatacept vs placebo on disease activity assessed with ESSDAI at in patients with pSS. Secondary: to assess efficacy of Abatacept on clinical, functional, laboratory, subjective, and histological parameters over 48 weeks in patients with pSS. To evaluate the safety of abatacept, by monitoring serious adverse events (SAE), adverse events (AE) related SAE and AE, treatment discontinuation related to SAE and AE, and lab abnormalities over 48 weeks in patients with pSS. Exploratory: to assess efficacy on laboratory parameters over 48 weeks in patients with pSS.

Study design: The first stage is a 24-week randomized, double-blind, placebo-controlled phase III study to assess the efficacy and safety of Abatacept (weekly SC administration of 125 mg Abatacept or placebo) in patients with pSS. The primary endpoint (ESSDAI) will be evaluated at 24 weeks. The second stage is composed of a 24-week open-label period in which both Abatacept and placebo treated patients will receive Abatacept for 24 weeks. The total study duration will be 48 weeks where after the study will be opened.

Study population: 88 adult pSS patients

Intervention: Weekly subcutaneous administration of 125 mg Abatacept up to 48 weeks.

Main endpoints: The primary endpoint is the difference in ESSDAI score between the Abatacept and the placebo group at 24 weeks. Secondary endpoints are clinical, functional, laboratory, subjective, and histological parameters and the prevalence of adverse events, treatment discontinuation and laboratory abnormalities.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • ESSDAI ≥ 5
  • Female or male ≥ 18 years
  • pSS according to the American European Consensus Group (AECG) classification criteria (6)
  • Disease duration ≤ 7 years at the moment of inclusion
  • pSS proven by parotid gland biopsy with characteristic features of SS
  • Women of child bearing (WOCBP) potential must be using an acceptable method of contraception to avoid pregnancy throughout the study and for up to 10 weeks after the last dose of study drug in such a manner that the risk of pregnancy is minimized.
  • Sexually active fertile men must use effective birth control if their partners are WOCBP

Exclusion Criteria:

  • Presence of any other connective tissue disease.
  • Flow rate of stimulated whole saliva &lt;0.05 ml/min in patients without extraglandular manifestations.
  • Positive pregnancy test or breast-feeding women.
  • Women with a child-bearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period.
  • History of alcohol or drug abuse or current alcohol or drug abuse.
  • History of any malignancy in the past 5 years, including MALT lymphoma in the last 5 years, or with a current suspicion for cancer, other than non-melanoma skin cell cancers (NMSC), cured by local resection or carcinoma in situ. Existing NMSCs should be removed, the lesion site healed, and residual cancer ruled out before administration of the study drug.
  • Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.
  • History of chronic or recurrent serious infections. (e.g. chronic pyelonephritis, osteomyelitis or bronchiectasis).
  • Subjects with serious bacterial infections within the last 3 month, unless treated and resolved with antibiotics
  • Subjects with herpes zoster or cytomegalovirus that resolved less than 2 months before potential enrollment.
  • Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be subjects with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (≥ 4 weeks).
  • Subjects must not be positive for hepatitis B surface antigen.
  • Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.
  • Subjects who have received any live vaccines within 3 months before potential enrollment.
  • Underlying cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal, haematological or neurological conditions, chronic or latent infectious diseases or immune deficiency which places the patient at an unacceptable risk for participation in the study.
  • Use of prednisone ≤10 mg less than 1 month before inclusion.
  • Use of pilocarpine, hydroxychloroquine, methotrexate, cyclophosphamide, cyclosporin, azathioprine, mycophenolate mofetil (MMF) and leflunomide less than 1 month before inclusion.
  • Previously treated with biological DMARDs either marketed or under investigation.
  • Lab abnormalities:

    1. Serum creatine ≥2.8 mg/dl (250 µmol/l)
    2. ASAT or ALAT outside 1.5 x upper normal range of the laboratory
    3. Hb ≤ 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females
    4. Neutrophil granulocytes less than 0.5 x 109/l
    5. Platelet count less than 50 x 109/l
  • Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
  • Subjects will be asked if they have allergies or adverse drug reactions. The investigator will withdraw subjects at unacceptable risk for participation from the study.
  • Prisoners or subjects who are involuntarily incarcerated.
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
  • Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02067910

Contacts
Contact: H. Bootsma, MD, PhD +3150-3613432 H.Bootsma@umcg.nl
Contact: G.S. van Zuiden +3150-3613432 G.S.van.Zuiden@umcg.nl

Locations
Netherlands
University Medical Center Groningen Recruiting
Groningen, Netherlands, 9700RB
Principal Investigator: H. Bootsma, MD, PhD         
Sponsors and Collaborators
University Medical Centre Groningen
Bristol-Myers Squibb
Investigators
Principal Investigator: H. Bootsma, MD, PhD University Medical Centre Groningen
  More Information

Publications:
Responsible Party: Dr. H. Bootsma, Principal investigator, University Medical Centre Groningen
ClinicalTrials.gov Identifier: NCT02067910     History of Changes
Other Study ID Numbers: IM101-473
Study First Received: February 14, 2014
Last Updated: August 21, 2014
Health Authority: Netherlands: Medical Ethics Review Committee (METC)
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by University Medical Centre Groningen:
Abatacept
Subcutaneous
Sjögren's syndrome
Treatment
Safety
Efficacy

Additional relevant MeSH terms:
Sjogren's Syndrome
Syndrome
Arthritis
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Disease
Dry Eye Syndromes
Eye Diseases
Immune System Diseases
Joint Diseases
Lacrimal Apparatus Diseases
Mouth Diseases
Musculoskeletal Diseases
Pathologic Processes
Rheumatic Diseases
Salivary Gland Diseases
Stomatognathic Diseases
Xerostomia
Abatacept
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014